| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/11/2012 | EP2474309A1 Pharmaceutical composition comprising ibuprofen, tramadol and a basic amino acid, preparation method thereof and use of same |
| 07/11/2012 | EP2474308A1 Pharmaceutical formulations containing bupropion hydrobromide |
| 07/11/2012 | EP2474307A2 Proliposomal drug delivery system |
| 07/11/2012 | EP2474306A1 Particle composition and medicinal composition comprising same |
| 07/11/2012 | EP2473607A2 Exon skipping therapy for functional amelioration of semi functional dystrophin in becker and duchenne muscular dystrophy |
| 07/11/2012 | EP2473513A1 Compounds as tyrosine kinase modulators |
| 07/11/2012 | EP2473510A1 Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer |
| 07/11/2012 | EP2473509A1 Kinase inhibitors, prodrug forms thereof and their use in therapy |
| 07/11/2012 | EP2473508A1 Compounds and compositions as tlr activity modulators |
| 07/11/2012 | EP2473506A2 Compounds and compositions for treating cancer |
| 07/11/2012 | EP2473505A1 Pyrazinylpyridines useful for the treatment of proliferative diseases |
| 07/11/2012 | EP2473504A2 Heterocyclic compounds for the inhibition of pask |
| 07/11/2012 | EP2473503A1 Bis-benzimidazole derivatives |
| 07/11/2012 | EP2473502A1 Heteroaryl compounds as kinase inhibitors |
| 07/11/2012 | EP2473501A1 Compounds as tyrosine kinase modulators |
| 07/11/2012 | EP2473500A2 Benzimidazole derivatives |
| 07/11/2012 | EP2473499A1 Bipyridines useful for the treatment of proliferative diseases |
| 07/11/2012 | EP2473498A1 Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| 07/11/2012 | EP2473495A1 Pharmaceutical compounds |
| 07/11/2012 | EP2473493A1 Methods of treating poxviral infections |
| 07/11/2012 | EP2473491A1 Morpholinone compounds as factor ixa inhibitors |
| 07/11/2012 | EP2473490A1 (thio)morpholine derivatives as s1p modulators |
| 07/11/2012 | EP2473489A1 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives |
| 07/11/2012 | EP2473488A1 Substituted heterocyclic derivatives for the treatment of pain and epilepsy |
| 07/11/2012 | EP2473487A1 Quinazolines as potassium ion channel inhibitors |
| 07/11/2012 | EP2473486A1 Novel pyrimidine and triazine hepcidine antagonists |
| 07/11/2012 | EP2473482A1 Methods of treating orthomyxoviral infections |
| 07/11/2012 | EP2473480A1 Novel antibacterial hydroxyphenyl compound |
| 07/11/2012 | EP2473479A1 Therapeutic aryl-am i do-aryl compounds and their use |
| 07/11/2012 | EP2473478A2 Novel uses |
| 07/11/2012 | EP2473199A1 Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders |
| 07/11/2012 | EP2473196A2 Sdf-1 delivery for treating ischemic tissue |
| 07/11/2012 | EP2473195A2 Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen |
| 07/11/2012 | EP2473182A2 Targeted delivery using tissue-specific peptidomimetic ligands |
| 07/11/2012 | EP2473176A1 Neuroprotective ganglioside compositions for use in treating or diagnosing huntington's disease |
| 07/11/2012 | EP2473175A1 Use of non-digestible oligosaccharides |
| 07/11/2012 | EP2473174A2 Ganglioside transmucosal formulations |
| 07/11/2012 | EP2473173A2 Treatment of glaucoma and other retinopathies with gangliosides |
| 07/11/2012 | EP2473172A2 Bisphosphonate compositions and methods for treating heart failure |
| 07/11/2012 | EP2473171A2 Methods of treating mitochondrial disorders using metalloporhyrins |
| 07/11/2012 | EP2473170A1 Use of aerosolized levofloxacin for treating cystic fibrosis |
| 07/11/2012 | EP2473168A1 Pharmaceutical formulations for indibulin |
| 07/11/2012 | EP2473167A1 Use of irbesartan for the preparation of a medicament for the prevention of hospitalization for heart failure. |
| 07/11/2012 | EP2473166A2 Treatment and prevention of secondary injury after trauma or damage to the central nervous system |
| 07/11/2012 | EP2473165A1 Combination medicament |
| 07/11/2012 | EP2473164A2 Antimicrobial ether guanidines |
| 07/11/2012 | EP2473161A2 Topical formulations comprising a steroid |
| 07/11/2012 | EP2473157A1 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 07/11/2012 | EP2473056A1 Chemical compounds |
| 07/11/2012 | EP2473054A1 Compositions and methods for treatment of leukemia |
| 07/11/2012 | EP2473053A1 Substituted xanthine derivatives |
| 07/11/2012 | EP2473052A1 Substituted xanthine derivatives |
| 07/11/2012 | EP2473051A1 Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations |
| 07/11/2012 | EP2473049A1 Bruton's tyrosine kinase inhibitors |
| 07/11/2012 | EP2473048A1 Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| 07/11/2012 | EP2473047A1 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 07/11/2012 | EP2473046A1 Iminosugars and methods of treating filoviral diseases |
| 07/11/2012 | EP2473045A1 Fatty acid niacin conjugates and their uses |
| 07/11/2012 | EP2473044A1 Tocotrienol compositions |
| 07/11/2012 | EP2473042A1 Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds |
| 07/11/2012 | EP2473041A1 Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| 07/11/2012 | EP2473040A1 Inhibiting the invasion and metastasis of cancer cells |
| 07/11/2012 | EP2473039A1 Durable treatment with 4-aminopyridine in patients with demyelination |
| 07/11/2012 | EP2473038A1 Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity |
| 07/11/2012 | EP2473037A2 Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same |
| 07/11/2012 | EP2473036A1 Antimicrobial compositions and products |
| 07/11/2012 | EP2415870A9 Rnai molecule for thymidylate synthase and use thereof |
| 07/11/2012 | EP2313408B1 Diketopiperidine derivatives as hiv attachment inhibitors |
| 07/11/2012 | EP2242491B1 Novel use of 3,3'-diindolylmethane |
| 07/11/2012 | EP2207773B1 Heterocyclic compound and pharmaceutical composition thereof |
| 07/11/2012 | EP2160386B1 Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds |
| 07/11/2012 | EP2139879B1 Quinoline derivatives for the treatment of inflammatory diseases |
| 07/11/2012 | EP2138489B1 Novel pyrimidine compound having benzyl(heterocyclicmethyl)amine structure and pharmaceutical product containing the same |
| 07/11/2012 | EP2094081B1 Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 07/11/2012 | EP2076132B1 P-toluene sulfonic acid salt of 5-amino-3-(2'-o-acetyl-3'-deoxy-beta -d-ribofuranosyl)-3h-thiazole [4, 5-d]pyrimidine-2-one and methods for preparation |
| 07/11/2012 | EP2034015B1 Immunostimulatory oligonucleotide and pharmaceutical application thereof |
| 07/11/2012 | EP2023922B1 Triazole derivatives ii |
| 07/11/2012 | EP2010535B1 Thioxanthine derivatives and their use as inhibitors of mpo |
| 07/11/2012 | EP2009100B1 siRNA SPECIFIC TO WT1 17AA(-)ISOFORM AND USE THEREOF |
| 07/11/2012 | EP1979316B1 Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as ep4 receptor agonists |
| 07/11/2012 | EP1973883B1 Novel compounds and methods for their production |
| 07/11/2012 | EP1971588B1 Tiglien-3-one derivatives |
| 07/11/2012 | EP1945265B1 Antiproliferative combination comprising cyc-682 and a cytotoxic agent |
| 07/11/2012 | EP1940401B1 Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| 07/11/2012 | EP1919477B1 Use of [2-(2-methylimidazol-1-yl)methyl]pyridine for treating sleep disorders |
| 07/11/2012 | EP1919458B1 Enterically coated cysteamine, cystamine and derivatives thereof |
| 07/11/2012 | EP1915156B1 Use of psychomotor stimulants and compositions containing them in a method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion |
| 07/11/2012 | EP1891074B1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 07/11/2012 | EP1866310B1 2,3-substituted fused pyrimidin-4(3h)-ones as vr1 antagonists |
| 07/11/2012 | EP1856097B1 Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| 07/11/2012 | EP1806134B1 Agent and food for preventing/improving functional digestive disorder |
| 07/11/2012 | EP1793809B1 Modified release ibuprofen dosage form |
| 07/11/2012 | EP1767216B1 Drug having regulatory cell ligand contained in liposome |
| 07/11/2012 | EP1750665B1 Biodegradable intravitreal tyrosine kinase inhibitors implants |
| 07/11/2012 | EP1740156B8 Method for the production of an abuse-proof, solid form of administration |
| 07/11/2012 | EP1715856B1 Atomoxetine formulations |
| 07/11/2012 | EP1708694B1 Compositions and methods for treating contracture |
| 07/11/2012 | EP1682142B1 M3 muscarinic acetylcholine receptor antagonists |
| 07/11/2012 | EP1678168B1 P70s6 kinase modulators and method of use |
| 07/11/2012 | EP1636335B1 Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase |